Shaanxi Maike Aote Technology

Shaanxi Macoat Biotech is a clinical-stage biopharmaceutical company based in Xi'an, China, specializing in the development of long-acting injectable drugs. The company utilizes a proprietary microsphere sustained-release technology platform to improve the delivery and efficacy of peptides and small molecules. Its advanced pipeline features MT-1002, a weekly exenatide formulation for type 2 diabetes, and MT-1005, a sustained-release octreotide for acromegaly, both of which are in late-stage clinical trials. Macoat's expertise extends from formulation design to large-scale GMP manufacturing of complex injectables. The company aims to provide high-quality, affordable alternatives to imported long-acting medications in the Chinese market. Macoat is publicly traded on the National Equities Exchange and Quotations (NEEQ) under the symbol 836843.